BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26190195)

  • 21. High CHI3L1 expression is associated with glioma patient survival.
    Steponaitis G; Skiriutė D; Kazlauskas A; Golubickaitė I; Stakaitis R; Tamašauskas A; Vaitkienė P
    Diagn Pathol; 2016 Apr; 11():42. PubMed ID: 27121858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas.
    Cooper LA; Gutman DA; Long Q; Johnson BA; Cholleti SR; Kurc T; Saltz JH; Brat DJ; Moreno CS
    PLoS One; 2010 Sep; 5(9):e12548. PubMed ID: 20838435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
    Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
    Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.
    Pollack IF; Hamilton RL; James CD; Finkelstein SD; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL;
    J Neurosurg; 2006 Nov; 105(5 Suppl):418-24. PubMed ID: 17328268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathogenic mutations in neurofibromin identifies a leucine-rich domain regulating glioma cell invasiveness.
    Fadhlullah SFB; Halim NBA; Yeo JYT; Ho RLY; Um P; Ang BT; Tang C; Ng WH; Virshup DM; Ho IAW
    Oncogene; 2019 Jul; 38(27):5367-5380. PubMed ID: 30967630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
    Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
    Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
    Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
    Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFRα activation.
    Azar S; Leventoux N; Ripoll C; Rigau V; Gozé C; Lorcy F; Bauchet L; Duffau H; Guichet PO; Rothhut B; Hugnot JP
    Glia; 2018 Feb; 66(2):239-255. PubMed ID: 29027701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular genetics of gliomas.
    Appin CL; Brat DJ
    Cancer J; 2014; 20(1):66-72. PubMed ID: 24445767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of SREBP2 and cholesterol metabolism related genes in TCGA glioma cohorts.
    Li D; Li S; Xue AZ; Smith Callahan LA; Liu Y
    Medicine (Baltimore); 2020 Mar; 99(12):e18815. PubMed ID: 32195924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
    Patil V; Mahalingam K
    Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.
    Lucas CG; Sloan EA; Gupta R; Wu J; Pratt D; Vasudevan HN; Ravindranathan A; Barreto J; Williams EA; Shai A; Whipple NS; Bruggers CS; Maher O; Nabors B; Rodriguez M; Samuel D; Brown M; Carmichael J; Lu R; Mirchia K; Sullivan DV; Pekmezci M; Tihan T; Bollen AW; Perry A; Banerjee A; Mueller S; Gupta N; Hervey-Jumper SL; Oberheim Bush NA; Daras M; Taylor JW; Butowski NA; de Groot J; Clarke JL; Raleigh DR; Costello JF; Phillips JJ; Reddy AT; Chang SM; Berger MS; Solomon DA
    Acta Neuropathol; 2022 Oct; 144(4):747-765. PubMed ID: 35945463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.
    Olar A; Raghunathan A; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Goodman JC; Fuller GN
    Ann Diagn Pathol; 2012 Jun; 16(3):161-70. PubMed ID: 22197544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.
    Alentorn A; Marie Y; Carpentier C; Boisselier B; Giry M; Labussière M; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Idbaih A
    Neuro Oncol; 2012 Nov; 14(11):1393-403. PubMed ID: 23074200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
    Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
    J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Macaulay RJ
    Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
    Herting CJ; Chen Z; Pitter KL; Szulzewsky F; Kaffes I; Kaluzova M; Park JC; Cimino PJ; Brennan C; Wang B; Hambardzumyan D
    Glia; 2017 Dec; 65(12):1914-1926. PubMed ID: 28836293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
    Chen R; Cohen AL; Colman H
    Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High level of Sema3C is associated with glioma malignancy.
    Vaitkienė P; Skiriutė D; Steponaitis G; Skauminas K; Tamašauskas A; Kazlauskas A
    Diagn Pathol; 2015 Jun; 10():58. PubMed ID: 26032848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.